how is stating that he added to his position pumping?? what exactly gets pumped when one states that they added shares?? your ego?
Tom..eps the number wasn't what people were looking at...yes, we knew they we were losing money still. I was looking at number of test sold and the progression of the facts.
association with the fund VERMILLION, under the Vermillion the Biotech??
accumulating this thing over the last several days since 2.98, hasn't been brought up on insider trading... How does this not raise any flags, that someone was clearly in the loop!
owing 2.67% SLIGHTLY OVER 2.3 MILLION SHARES OF THE SHARES OUTSTANDING SHARES OF kerx, AND THE OWNING 12 MILLION SHARES OF mstx... Not that every investment is successful, but Franklin seems to like the odds!
The big joke down at the station back in the day was ANX to 25.......hahaha. That's 25 dollars! To this day I still laugh! I am holding out hope on this company as I have been in since 2005. If nothing more, for my cousins sake and his 135,000 shares....I hope it does well.
Form 8-K for MAST THERAPEUTICS, INC.
Other Events, Financial Statements and Exhibits
Item 8.01. Other Events.
Beginning on February 24, 2014, the information attached as Exhibit 99.1 to this report relating to Mast Therapeutics, Inc. (the "Company") and its development programs will be presented from time to time by the Company at various investor and analyst meetings.
Item 9.01. Financial Statements and Exhibits.
The list of exhibits called for by this Item is incorporated by reference to the Exhibit Index filed with this report.
By filing this report, including the information contained in Exhibit 99.1 attached hereto, the Company makes no admission as to the materiality of any information in this report. The information contained in Exhibit 99.1 hereto is summary information that is intended to be considered in the context of the Company's filings with the U.S. Securities and Exchange Commission (the "SEC"), including its Annual Report on Form 10-K filed on March 19, 2013, its quarterly reports on Form 10-Q for the periods ended March 31, 2013, June 30, 2013 and September 30, 2013, and other public announcements that the Company makes, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in this report, although it may do so from time to time as it believes is appropriate. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases, or through other public disclosure.
Mast Therapeutics cautions you that statements included in this report, including in Exhibit 99.1 attached hereto, that are not a description of historical facts are forward-looking statements that are based on the Company's current expectations and assumptions. Such forward-looking statements include, but are not limited to, statements regarding the Company's development
First off this is a public forum, so at this point I will not elaborate on what tricks are planned. secondly, where in my post did I give any praise to Culley?? Don't put words in my mouth. We are getting in now, well in advance of the significant news that will be out on the sickle cell drug of mst 188. How it reacts with the abnormal cells in the human body will be just the beginning. It is my belief that the label it has received as an orphan drug is as well just the beginning. There are 100,000 people in the US with Sickle cell. This is not huge amount, but it is a way to show exactly what this drug is capable of doing, and how it can be applied to other areas with a more significant need. As for my average share price, I have begun accumulating at these levels, and will continue to do so. My average share price is at $3.40 a share at this point. My reference to Kerx was to show that when things look so bleak there are times when there is light at the end of the title. Sorry you couldn't read into the comparison a little further. I know kerx completed phase three trials of Zerenex for the treatment of elevated phosphate levels in patients with end stage renial disease. It also I in phase two to be used for patients who have chronic kidney disease. I do like MSTX pipeline in comparison to KERX, and as many have said it only a matter of time that this stock heads higher as the time approaches to gain possible approval of there drug. It has no choice, but to head higher based on the prospects. For now it is dead money, and if you are looking for that eventual big pay day you must continue to be patient.
because eps/ conference call will be another indication of what growth is being made. That's why.